{
    "cancer_type": "Esophageal Cancer",
    "title": "Esophageal Cancer—Patient Version",
    "url": "https://www.cancer.gov/types/esophageal",
    "content": [
        {
            "section": "Paragraph",
            "text": "The most common types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. These two forms of esophageal cancer tend to develop in different parts of the esophagus and are driven by different genetic changes. Explore the links on this page to learn more about esophageal cancer prevention, screening, treatment, statistics, research, and clinical trials."
        },
        {
            "section": "Paragraph",
            "text": "Esophageal Cancer | Did You Know?"
        },
        {
            "section": "Paragraph",
            "text": "The information in this section is meant to help you cope with the many issues and concerns that occur when you have cancer."
        },
        {
            "section": "Paragraph",
            "text": "Trial Establishes Preferred Treatment for Some People with Esophageal Cancer"
        },
        {
            "section": "Paragraph",
            "text": "Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer"
        },
        {
            "section": "Paragraph",
            "text": "For Esophageal Cancer, Immunotherapy Likely to Play Larger Role"
        },
        {
            "section": "Paragraph",
            "text": "Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer"
        },
        {
            "section": "Paragraph",
            "text": "National Cancer Institute\nat the National Institutes of Health"
        }
    ],
    "related_links": [
        "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/treatment",
        "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/prevention",
        "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/screening",
        "https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy",
        "https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations",
        "https://www.cancer.gov/news-events/cancer-currents-blog/2020/esophageal-cancer-immunotherapy-pembrolizumab-nivolumab"
    ],
    "related_pages": {
        "Treatment Clinical Trials for Esophageal Cancer": {
            "cancer_type": "Esophageal Cancer",
            "title": "Treatment Clinical Trials for Esophageal Cancer",
            "url": "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/treatment",
            "content": [
                {
                    "section": "Paragraph",
                    "text": "National Cancer Institute\nat the National Institutes of Health"
                }
            ],
            "related_links": [
                "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/treatment#main-content"
            ],
            "related_pages": {
                "Treatment Clinical Trials for Esophageal Cancer": {
                    "cancer_type": "Esophageal Cancer",
                    "title": "Treatment Clinical Trials for Esophageal Cancer",
                    "url": "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/treatment",
                    "content": [
                        {
                            "section": "Paragraph",
                            "text": "National Cancer Institute\nat the National Institutes of Health"
                        }
                    ],
                    "related_links": [
                        "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/treatment#main-content"
                    ],
                    "related_pages": {}
                }
            }
        },
        "Prevention Clinical Trials for Esophageal Cancer": {
            "cancer_type": "Esophageal Cancer",
            "title": "Prevention Clinical Trials for Esophageal Cancer",
            "url": "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/prevention",
            "content": [
                {
                    "section": "Paragraph",
                    "text": "National Cancer Institute\nat the National Institutes of Health"
                }
            ],
            "related_links": [
                "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/prevention#main-content"
            ],
            "related_pages": {
                "Prevention Clinical Trials for Esophageal Cancer": {
                    "cancer_type": "Esophageal Cancer",
                    "title": "Prevention Clinical Trials for Esophageal Cancer",
                    "url": "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/prevention",
                    "content": [
                        {
                            "section": "Paragraph",
                            "text": "National Cancer Institute\nat the National Institutes of Health"
                        }
                    ],
                    "related_links": [
                        "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/prevention#main-content"
                    ],
                    "related_pages": {}
                }
            }
        },
        "Screening Clinical Trials for Esophageal Cancer": {
            "cancer_type": "Esophageal Cancer",
            "title": "Screening Clinical Trials for Esophageal Cancer",
            "url": "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/screening",
            "content": [
                {
                    "section": "Paragraph",
                    "text": "National Cancer Institute\nat the National Institutes of Health"
                }
            ],
            "related_links": [
                "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/screening#main-content"
            ],
            "related_pages": {
                "Screening Clinical Trials for Esophageal Cancer": {
                    "cancer_type": "Esophageal Cancer",
                    "title": "Screening Clinical Trials for Esophageal Cancer",
                    "url": "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/screening",
                    "content": [
                        {
                            "section": "Paragraph",
                            "text": "National Cancer Institute\nat the National Institutes of Health"
                        }
                    ],
                    "related_links": [
                        "https://www.cancer.gov/research/participate/clinical-trials/disease/esophageal-cancer/screening#main-content"
                    ],
                    "related_pages": {}
                }
            }
        },
        "Trial Establishes Preferred Treatment for Some People with Esophageal Cancer": {
            "cancer_type": "Esophageal Cancer",
            "title": "Trial Establishes Preferred Treatment for Some People with Esophageal Cancer",
            "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy",
            "content": [
                {
                    "section": "Paragraph",
                    "text": "July 9, 2024, by Linda Wang"
                },
                {
                    "section": "Paragraph",
                    "text": "In locally advanced esophageal cancer, the disease has spread just outside of the esophagus, including to nearby lymph nodes, but not to other parts of the body."
                },
                {
                    "section": "Paragraph",
                    "text": "A large clinical trial looks to have settled a debate over how best to treat most people with locally advanced esophageal cancer, where the disease has spread just outside of the esophagus but not to other parts of the body."
                },
                {
                    "section": "Paragraph",
                    "text": "Typically, these people get one of two treatments: chemotherapy followed by surgery and then more chemotherapy, or chemotherapy and radiation followed by surgery and no further treatment."
                },
                {
                    "section": "Paragraph",
                    "text": "It’s been unclear, however, if one approach was more effective than the other."
                },
                {
                    "section": "Paragraph",
                    "text": "In the trial, people treated with chemotherapy both before and after surgery, which is known as perioperative chemotherapy, lived considerably longer than those who received chemotherapy and radiation before surgery\nExit Disclaimer\n, known as neoadjuvant treatment."
                },
                {
                    "section": "Paragraph",
                    "text": "Based on the study’s findings, perioperative chemotherapy should be the recommended approach for people with locally advanced esophageal cancer, said Jens Hoeppner, M.D., of the University of Bielefeld in Germany, who led the study. Dr. Hoeppner presented the findings at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2."
                },
                {
                    "section": "Paragraph",
                    "text": "“The results have been long awaited among those of us who treat esophageal cancer,” said Karyn A. Goodman, M.D., of the Icahn School of Medicine at Mount Sinai in New York, who discussed the results during the meeting but was not involved in the study."
                },
                {
                    "section": "Paragraph",
                    "text": "Dr. Goodman also noted, however, that the treatment landscape for esophageal cancer is rapidly evolving. Although it’s important to have some resolution to this particular debate, she said, newer treatments, including immunotherapies, are also now an option for people with locally advanced esophageal cancer."
                },
                {
                    "section": "Paragraph",
                    "text": "In addition, researchers are also testing whether combining these regimens with other therapies can lead to even better outcomes for patients. In other words, she stressed, how locally advanced esophageal cancer is treated is going to continue to evolve in the coming years."
                },
                {
                    "section": "Paragraph",
                    "text": "In the United States, it is estimated that more than 22,000 people will be diagnosed with esophageal cancer this year. Approximately half of these cases will be diagnosed at a locally advanced stage."
                },
                {
                    "section": "Paragraph",
                    "text": "FLOT regimen: Four cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel over 8 weeks, followed by surgery 4 to 6 weeks later. After leaving the hospital, patients receive the same chemotherapy regimen 4 to 6 weeks later."
                },
                {
                    "section": "Paragraph",
                    "text": "CROSS regimen: Radiation (41.4 Gy), along with five cycles of paclitaxel and carboplatin over 5 weeks, followed by surgery 4 to 6 weeks later."
                },
                {
                    "section": "Paragraph",
                    "text": "Surgery was long the primary treatment for locally advanced esophageal cancer. That changed over the past two decades, with several large trials showing that the addition of perioperative chemotherapy or neoadjuvant chemotherapy plus radiation therapy improved how long people lived."
                },
                {
                    "section": "Paragraph",
                    "text": "From those trials, two options emerged as the recommended treatments: a perioperative chemotherapy regimen called FLOT and a neoadjuvant chemotherapy and radiation regimen called CROSS (see box)."
                },
                {
                    "section": "Paragraph",
                    "text": "With two proven, highly effective treatment approaches available, Dr. Hoeppner and his colleagues decided to launch a trial to answer a question that arose frequently among oncologists: Which one is best for their patients?"
                },
                {
                    "section": "Paragraph",
                    "text": "In the new trial, dubbed ESOPEC and funded by the German Research Foundation, 438 people with locally advanced esophageal cancer were randomly assigned to receive either perioperative chemotherapy with the FLOT regimen or neoadjuvant chemoradiation with the CROSS regimen."
                },
                {
                    "section": "Paragraph",
                    "text": "After completing treatment, 35 of the 191 patients in the FLOT group had complete disappearance of their tumor, known as a complete response, compared with 24 of the 180 patients in the CROSS group."
                },
                {
                    "section": "Paragraph",
                    "text": "Patients who received the FLOT regimen lived a median of 5 years and 6 months, compared with about 3 years for patients in the CROSS group. Three years after completion of treatment, 57% of people in the FLOT group and 51% of patients in the CROSS group were still alive."
                },
                {
                    "section": "Paragraph",
                    "text": "The rate of complications after surgery was similar among both groups. However, within 90 days of surgery, about 3% of participants in the FLOT group had died, compared with nearly 6% of participants in the CROSS group."
                },
                {
                    "section": "Paragraph",
                    "text": "The FLOT regimen should now be the standard of care for most people with locally advanced esophageal cancer, Dr. Goodman agreed."
                },
                {
                    "section": "Paragraph",
                    "text": "But with the rise of immunotherapies, that may change."
                },
                {
                    "section": "Paragraph",
                    "text": "For example, a trial called CheckMate 577 showed that giving the immunotherapy drug nivolumab (Opdivo) after the CROSS regimen and surgery may be an effective option."
                },
                {
                    "section": "Paragraph",
                    "text": "In that trial, which included people considered to be at high risk of their cancer coming back, giving nivolumab after surgery improved how long participants lived without their disease returning."
                },
                {
                    "section": "Paragraph",
                    "text": "So particularly in combination with nivolumab, CROSS may have some advantages for certain patients, Dr. Goodman pointed out."
                },
                {
                    "section": "Paragraph",
                    "text": "For example, people with esophageal cancer tend to be elderly and have other health problems, she explained. “The CROSS regimen is … very well tolerated by these patients. And I think … the CROSS regimen, followed by adjuvant nivolumab, is still a potential option for many of these patients,” Dr. Goodman said."
                },
                {
                    "section": "Paragraph",
                    "text": "Other studies are also testing the addition of immunotherapies, including other immune checkpoint inhibitors, into existing treatment regimens for locally advanced esophageal cancer. And still other studies are evaluating the combination of FLOT and CROSS."
                },
                {
                    "section": "Paragraph",
                    "text": "“Given the poor prognosis with this disease, we need to continue to develop clinical trials [involving] novel treatment combinations and select patients who will respond best to specific treatments,” Dr. Goodman said."
                },
                {
                    "section": "Paragraph",
                    "text": "Program Helps Medically Underserved, Minority Cancer Survivors Be More Active"
                },
                {
                    "section": "Paragraph",
                    "text": "Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases"
                },
                {
                    "section": "Paragraph",
                    "text": "If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Trial Establishes Preferred Treatment for Some People with Esophageal Cancer was originally published by the National Cancer Institute.”"
                },
                {
                    "section": "Paragraph",
                    "text": "February 13, 2025, by Carmen Phillips"
                },
                {
                    "section": "Paragraph",
                    "text": "January 2, 2025, by Linda Wang"
                },
                {
                    "section": "Paragraph",
                    "text": "December 11, 2024, by Nadia Jaber"
                },
                {
                    "section": "Paragraph",
                    "text": "National Cancer Institute\nat the National Institutes of Health"
                }
            ],
            "related_links": [
                "https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy#main-content",
                "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States)."
            ],
            "related_pages": {
                "Trial Establishes Preferred Treatment for Some People with Esophageal Cancer": {
                    "cancer_type": "Esophageal Cancer",
                    "title": "Trial Establishes Preferred Treatment for Some People with Esophageal Cancer",
                    "url": "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                    "content": [
                        {
                            "section": "Paragraph",
                            "text": "July 9, 2024, by Linda Wang"
                        },
                        {
                            "section": "Paragraph",
                            "text": "In locally advanced esophageal cancer, the disease has spread just outside of the esophagus, including to nearby lymph nodes, but not to other parts of the body."
                        },
                        {
                            "section": "Paragraph",
                            "text": "A large clinical trial looks to have settled a debate over how best to treat most people with locally advanced esophageal cancer, where the disease has spread just outside of the esophagus but not to other parts of the body."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Typically, these people get one of two treatments: chemotherapy followed by surgery and then more chemotherapy, or chemotherapy and radiation followed by surgery and no further treatment."
                        },
                        {
                            "section": "Paragraph",
                            "text": "It’s been unclear, however, if one approach was more effective than the other."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In the trial, people treated with chemotherapy both before and after surgery, which is known as perioperative chemotherapy, lived considerably longer than those who received chemotherapy and radiation before surgery\nExit Disclaimer\n, known as neoadjuvant treatment."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Based on the study’s findings, perioperative chemotherapy should be the recommended approach for people with locally advanced esophageal cancer, said Jens Hoeppner, M.D., of the University of Bielefeld in Germany, who led the study. Dr. Hoeppner presented the findings at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2."
                        },
                        {
                            "section": "Paragraph",
                            "text": "“The results have been long awaited among those of us who treat esophageal cancer,” said Karyn A. Goodman, M.D., of the Icahn School of Medicine at Mount Sinai in New York, who discussed the results during the meeting but was not involved in the study."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Dr. Goodman also noted, however, that the treatment landscape for esophageal cancer is rapidly evolving. Although it’s important to have some resolution to this particular debate, she said, newer treatments, including immunotherapies, are also now an option for people with locally advanced esophageal cancer."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In addition, researchers are also testing whether combining these regimens with other therapies can lead to even better outcomes for patients. In other words, she stressed, how locally advanced esophageal cancer is treated is going to continue to evolve in the coming years."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In the United States, it is estimated that more than 22,000 people will be diagnosed with esophageal cancer this year. Approximately half of these cases will be diagnosed at a locally advanced stage."
                        },
                        {
                            "section": "Paragraph",
                            "text": "FLOT regimen: Four cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel over 8 weeks, followed by surgery 4 to 6 weeks later. After leaving the hospital, patients receive the same chemotherapy regimen 4 to 6 weeks later."
                        },
                        {
                            "section": "Paragraph",
                            "text": "CROSS regimen: Radiation (41.4 Gy), along with five cycles of paclitaxel and carboplatin over 5 weeks, followed by surgery 4 to 6 weeks later."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Surgery was long the primary treatment for locally advanced esophageal cancer. That changed over the past two decades, with several large trials showing that the addition of perioperative chemotherapy or neoadjuvant chemotherapy plus radiation therapy improved how long people lived."
                        },
                        {
                            "section": "Paragraph",
                            "text": "From those trials, two options emerged as the recommended treatments: a perioperative chemotherapy regimen called FLOT and a neoadjuvant chemotherapy and radiation regimen called CROSS (see box)."
                        },
                        {
                            "section": "Paragraph",
                            "text": "With two proven, highly effective treatment approaches available, Dr. Hoeppner and his colleagues decided to launch a trial to answer a question that arose frequently among oncologists: Which one is best for their patients?"
                        },
                        {
                            "section": "Paragraph",
                            "text": "In the new trial, dubbed ESOPEC and funded by the German Research Foundation, 438 people with locally advanced esophageal cancer were randomly assigned to receive either perioperative chemotherapy with the FLOT regimen or neoadjuvant chemoradiation with the CROSS regimen."
                        },
                        {
                            "section": "Paragraph",
                            "text": "After completing treatment, 35 of the 191 patients in the FLOT group had complete disappearance of their tumor, known as a complete response, compared with 24 of the 180 patients in the CROSS group."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Patients who received the FLOT regimen lived a median of 5 years and 6 months, compared with about 3 years for patients in the CROSS group. Three years after completion of treatment, 57% of people in the FLOT group and 51% of patients in the CROSS group were still alive."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The rate of complications after surgery was similar among both groups. However, within 90 days of surgery, about 3% of participants in the FLOT group had died, compared with nearly 6% of participants in the CROSS group."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The FLOT regimen should now be the standard of care for most people with locally advanced esophageal cancer, Dr. Goodman agreed."
                        },
                        {
                            "section": "Paragraph",
                            "text": "But with the rise of immunotherapies, that may change."
                        },
                        {
                            "section": "Paragraph",
                            "text": "For example, a trial called CheckMate 577 showed that giving the immunotherapy drug nivolumab (Opdivo) after the CROSS regimen and surgery may be an effective option."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In that trial, which included people considered to be at high risk of their cancer coming back, giving nivolumab after surgery improved how long participants lived without their disease returning."
                        },
                        {
                            "section": "Paragraph",
                            "text": "So particularly in combination with nivolumab, CROSS may have some advantages for certain patients, Dr. Goodman pointed out."
                        },
                        {
                            "section": "Paragraph",
                            "text": "For example, people with esophageal cancer tend to be elderly and have other health problems, she explained. “The CROSS regimen is … very well tolerated by these patients. And I think … the CROSS regimen, followed by adjuvant nivolumab, is still a potential option for many of these patients,” Dr. Goodman said."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Other studies are also testing the addition of immunotherapies, including other immune checkpoint inhibitors, into existing treatment regimens for locally advanced esophageal cancer. And still other studies are evaluating the combination of FLOT and CROSS."
                        },
                        {
                            "section": "Paragraph",
                            "text": "“Given the poor prognosis with this disease, we need to continue to develop clinical trials [involving] novel treatment combinations and select patients who will respond best to specific treatments,” Dr. Goodman said."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Program Helps Medically Underserved, Minority Cancer Survivors Be More Active"
                        },
                        {
                            "section": "Paragraph",
                            "text": "Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases"
                        },
                        {
                            "section": "Paragraph",
                            "text": "If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Trial Establishes Preferred Treatment for Some People with Esophageal Cancer was originally published by the National Cancer Institute.”"
                        },
                        {
                            "section": "Paragraph",
                            "text": "February 13, 2025, by Carmen Phillips"
                        },
                        {
                            "section": "Paragraph",
                            "text": "January 2, 2025, by Linda Wang"
                        },
                        {
                            "section": "Paragraph",
                            "text": "December 11, 2024, by Nadia Jaber"
                        },
                        {
                            "section": "Paragraph",
                            "text": "National Cancer Institute\nat the National Institutes of Health"
                        }
                    ],
                    "related_links": [
                        "https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy#main-content",
                        "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                        "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States)."
                    ],
                    "related_pages": {}
                }
            }
        },
        "Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer": {
            "cancer_type": "Esophageal Cancer",
            "title": "Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer",
            "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations",
            "content": [
                {
                    "section": "Paragraph",
                    "text": "June 17, 2021, by Edward Winstead"
                },
                {
                    "section": "Paragraph",
                    "text": "An x-ray of the esophagus and upper gastrointestinal tract following a barium swallow test."
                },
                {
                    "section": "Paragraph",
                    "text": "UPDATE: On May 27, 2022, the Food and Drug Administration (FDA) approved two different nivolumab (Opdivo)-based drug combinations as an initial treatment for some people with advanced or metastatic esophageal cancer that can’t be treated with surgery."
                },
                {
                    "section": "Paragraph",
                    "text": "The approval covers the use of nivolumab plus chemotherapy and nivolumab plus ipilimumab (Yervoy) for the treatment of esophageal squamous cell carcinoma, which starts in the cells that line the esophagus. The approvals are based on the results of the CheckMate 648 trial, which are described in the story below."
                },
                {
                    "section": "Paragraph",
                    "text": "For some people with advanced esophageal cancer, two immunotherapy-based combination therapies are more effective than chemotherapy alone, which is the current standard treatment, according to the results of a large clinical trial."
                },
                {
                    "section": "Paragraph",
                    "text": "The combination therapies evaluated in the trial were the immune checkpoint inhibitor nivolumab (Opdivo) plus chemotherapy and nivolumab plus the immune checkpoint inhibitor ipilimumab (Yervoy). The trial, CheckMate 648, included 970 patients with advanced or metastatic esophageal squamous cell carcinoma that could not be treated surgically."
                },
                {
                    "section": "Paragraph",
                    "text": "When compared with chemotherapy alone, both combination therapies improved how long patients lived by several months\nExit Disclaimer\n, according to results presented at the American Society of Clinical Oncology (ASCO) annual meeting on June 3."
                },
                {
                    "section": "Paragraph",
                    "text": "Each of the combination therapies represents a new standard of care for patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma, said Ian Chau, M.D., of the Royal Marsden Hospital in Sutton, the United Kingdom, who presented the findings."
                },
                {
                    "section": "Paragraph",
                    "text": "Most patients diagnosed with advanced or metastatic esophageal squamous cell carcinoma who receive standard chemotherapy do not survive for a year, noted Dr. Chau."
                },
                {
                    "section": "Paragraph",
                    "text": "Julie Gralow, M.D., ASCO’s chief medical officer, agreed that the combination therapies would likely expand treatment options for some patients. These therapies, she noted during a press briefing, were superior to standard chemotherapy, particularly among patients whose tumors express certain levels of a protein called PD-L1."
                },
                {
                    "section": "Paragraph",
                    "text": "The combination of nivolumab and ipilimumab is the first treatment regimen without chemotherapy shown to benefit patients with previously untreated advanced esophageal cancer, Dr. Gralow said."
                },
                {
                    "section": "Paragraph",
                    "text": "The two most common forms of esophageal cancer are squamous cell carcinoma, which begins in cells lining the esophagus, and adenocarcinoma, which begins in cells that make and release mucus and other fluids."
                },
                {
                    "section": "Paragraph",
                    "text": "In the United States, adenocarcinoma is the most common form of the disease and is diagnosed primarily in older white men. Squamous cell carcinoma is more common outside of the United States, particularly in less developed countries."
                },
                {
                    "section": "Paragraph",
                    "text": "Following several recent drug approvals by the Food and Drug Administration, immunotherapy—both alone and with chemotherapy—has become a standard treatment for some forms of esophageal cancer, noted Carmen Allegra, M.D., a special advisor to NCI’s Division of Cancer Treatment and Diagnosis, who was not involved in the clinical trial."
                },
                {
                    "section": "Paragraph",
                    "text": "“The new findings are important research results that will inform decisions about initial therapy for some patients with advanced esophageal cancers,” said Dr. Allegra, who specializes in the treatment of gastrointestinal cancers."
                },
                {
                    "section": "Paragraph",
                    "text": "In the new study, 49% of the patients in each combination therapy group and 48% of the chemotherapy group had tumors that were PD-L1 positive (that is, the tumors had PD-L1 levels of 1% or higher). PD-L1 is involved in the body’s immune response and is a potential indicator of responsiveness to immune checkpoint inhibitors."
                },
                {
                    "section": "Paragraph",
                    "text": "With a minimum of 13 months follow-up, overall survival with both of the combinations was better among patients whose tumors were PD-L1 positive, as was the percentage of patients whose tumors shrank (response rate). \n \nThe amount of time before the disease worsened (progression-free survival) also was improved among the PD-L1-positive patients in the nivolumab-plus-chemotherapy group, compared with chemotherapy alone."
                },
                {
                    "section": "Paragraph",
                    "text": "Different types of side effects occurred among patients who received a chemotherapy-containing regimen and those who did not. The most common side effects associated with the chemotherapy-containing regimens were nausea, decreased appetite, and inflammation of the mouth (stomatitis). Side effects from the dual-immunotherapy regimen included rash, itching, and hypothyroidism."
                },
                {
                    "section": "Paragraph",
                    "text": "The clinical trial was sponsored by Bristol Myers Squibb, the maker of nivolumab and ipilimumab."
                },
                {
                    "section": "Paragraph",
                    "text": "The new findings build on recent studies testing immunotherapy drugs in esophageal cancer. In 2019, the drug pembrolizumab (Keytruda) was approved for the treatment of some patients with advanced esophageal cancer."
                },
                {
                    "section": "Paragraph",
                    "text": "The following year, researchers reported that using nivolumab plus chemotherapy as an initial treatment for advanced stomach cancer improved overall survival. That study, CheckMate 649, included patients with esophageal adenocarcinoma and patients with gastroesophageal junction cancer, which occurs where the esophagus meets the stomach."
                },
                {
                    "section": "Paragraph",
                    "text": "“We now have better regimens for patients with advanced esophageal cancer and with gastroesophageal junction cancer,” said Dr. Allegra. “And we are learning how to best use immunotherapy in these diseases.”"
                },
                {
                    "section": "Paragraph",
                    "text": "The evidence that some patients with advanced esophageal cancer will benefit from a combination of immunotherapy and chemotherapy is “very solid,” Dr. Allegra said. “The new wrinkle is the use of the immunotherapy combination without chemotherapy.”"
                },
                {
                    "section": "Paragraph",
                    "text": "Because the current study was not designed to be a direct comparison between nivolumab with chemotherapy or ipilimumab, more research is needed to learn which patients might benefit most from one regimen or the other, he added."
                },
                {
                    "section": "Paragraph",
                    "text": "Should People Over Age 75 Be Screened for Colorectal Cancer?"
                },
                {
                    "section": "Paragraph",
                    "text": "Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma"
                },
                {
                    "section": "Paragraph",
                    "text": "If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer was originally published by the National Cancer Institute.”"
                },
                {
                    "section": "Paragraph",
                    "text": "February 13, 2025, by Carmen Phillips"
                },
                {
                    "section": "Paragraph",
                    "text": "January 2, 2025, by Linda Wang"
                },
                {
                    "section": "Paragraph",
                    "text": "December 11, 2024, by Nadia Jaber"
                },
                {
                    "section": "Paragraph",
                    "text": "National Cancer Institute\nat the National Institutes of Health"
                }
            ],
            "related_links": [
                "https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations#main-content",
                "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States)."
            ],
            "related_pages": {
                "Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer": {
                    "cancer_type": "Esophageal Cancer",
                    "title": "Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer",
                    "url": "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                    "content": [
                        {
                            "section": "Paragraph",
                            "text": "June 17, 2021, by Edward Winstead"
                        },
                        {
                            "section": "Paragraph",
                            "text": "An x-ray of the esophagus and upper gastrointestinal tract following a barium swallow test."
                        },
                        {
                            "section": "Paragraph",
                            "text": "UPDATE: On May 27, 2022, the Food and Drug Administration (FDA) approved two different nivolumab (Opdivo)-based drug combinations as an initial treatment for some people with advanced or metastatic esophageal cancer that can’t be treated with surgery."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The approval covers the use of nivolumab plus chemotherapy and nivolumab plus ipilimumab (Yervoy) for the treatment of esophageal squamous cell carcinoma, which starts in the cells that line the esophagus. The approvals are based on the results of the CheckMate 648 trial, which are described in the story below."
                        },
                        {
                            "section": "Paragraph",
                            "text": "For some people with advanced esophageal cancer, two immunotherapy-based combination therapies are more effective than chemotherapy alone, which is the current standard treatment, according to the results of a large clinical trial."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The combination therapies evaluated in the trial were the immune checkpoint inhibitor nivolumab (Opdivo) plus chemotherapy and nivolumab plus the immune checkpoint inhibitor ipilimumab (Yervoy). The trial, CheckMate 648, included 970 patients with advanced or metastatic esophageal squamous cell carcinoma that could not be treated surgically."
                        },
                        {
                            "section": "Paragraph",
                            "text": "When compared with chemotherapy alone, both combination therapies improved how long patients lived by several months\nExit Disclaimer\n, according to results presented at the American Society of Clinical Oncology (ASCO) annual meeting on June 3."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Each of the combination therapies represents a new standard of care for patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma, said Ian Chau, M.D., of the Royal Marsden Hospital in Sutton, the United Kingdom, who presented the findings."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Most patients diagnosed with advanced or metastatic esophageal squamous cell carcinoma who receive standard chemotherapy do not survive for a year, noted Dr. Chau."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Julie Gralow, M.D., ASCO’s chief medical officer, agreed that the combination therapies would likely expand treatment options for some patients. These therapies, she noted during a press briefing, were superior to standard chemotherapy, particularly among patients whose tumors express certain levels of a protein called PD-L1."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The combination of nivolumab and ipilimumab is the first treatment regimen without chemotherapy shown to benefit patients with previously untreated advanced esophageal cancer, Dr. Gralow said."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The two most common forms of esophageal cancer are squamous cell carcinoma, which begins in cells lining the esophagus, and adenocarcinoma, which begins in cells that make and release mucus and other fluids."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In the United States, adenocarcinoma is the most common form of the disease and is diagnosed primarily in older white men. Squamous cell carcinoma is more common outside of the United States, particularly in less developed countries."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Following several recent drug approvals by the Food and Drug Administration, immunotherapy—both alone and with chemotherapy—has become a standard treatment for some forms of esophageal cancer, noted Carmen Allegra, M.D., a special advisor to NCI’s Division of Cancer Treatment and Diagnosis, who was not involved in the clinical trial."
                        },
                        {
                            "section": "Paragraph",
                            "text": "“The new findings are important research results that will inform decisions about initial therapy for some patients with advanced esophageal cancers,” said Dr. Allegra, who specializes in the treatment of gastrointestinal cancers."
                        },
                        {
                            "section": "Paragraph",
                            "text": "In the new study, 49% of the patients in each combination therapy group and 48% of the chemotherapy group had tumors that were PD-L1 positive (that is, the tumors had PD-L1 levels of 1% or higher). PD-L1 is involved in the body’s immune response and is a potential indicator of responsiveness to immune checkpoint inhibitors."
                        },
                        {
                            "section": "Paragraph",
                            "text": "With a minimum of 13 months follow-up, overall survival with both of the combinations was better among patients whose tumors were PD-L1 positive, as was the percentage of patients whose tumors shrank (response rate). \n \nThe amount of time before the disease worsened (progression-free survival) also was improved among the PD-L1-positive patients in the nivolumab-plus-chemotherapy group, compared with chemotherapy alone."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Different types of side effects occurred among patients who received a chemotherapy-containing regimen and those who did not. The most common side effects associated with the chemotherapy-containing regimens were nausea, decreased appetite, and inflammation of the mouth (stomatitis). Side effects from the dual-immunotherapy regimen included rash, itching, and hypothyroidism."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The clinical trial was sponsored by Bristol Myers Squibb, the maker of nivolumab and ipilimumab."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The new findings build on recent studies testing immunotherapy drugs in esophageal cancer. In 2019, the drug pembrolizumab (Keytruda) was approved for the treatment of some patients with advanced esophageal cancer."
                        },
                        {
                            "section": "Paragraph",
                            "text": "The following year, researchers reported that using nivolumab plus chemotherapy as an initial treatment for advanced stomach cancer improved overall survival. That study, CheckMate 649, included patients with esophageal adenocarcinoma and patients with gastroesophageal junction cancer, which occurs where the esophagus meets the stomach."
                        },
                        {
                            "section": "Paragraph",
                            "text": "“We now have better regimens for patients with advanced esophageal cancer and with gastroesophageal junction cancer,” said Dr. Allegra. “And we are learning how to best use immunotherapy in these diseases.”"
                        },
                        {
                            "section": "Paragraph",
                            "text": "The evidence that some patients with advanced esophageal cancer will benefit from a combination of immunotherapy and chemotherapy is “very solid,” Dr. Allegra said. “The new wrinkle is the use of the immunotherapy combination without chemotherapy.”"
                        },
                        {
                            "section": "Paragraph",
                            "text": "Because the current study was not designed to be a direct comparison between nivolumab with chemotherapy or ipilimumab, more research is needed to learn which patients might benefit most from one regimen or the other, he added."
                        },
                        {
                            "section": "Paragraph",
                            "text": "Should People Over Age 75 Be Screened for Colorectal Cancer?"
                        },
                        {
                            "section": "Paragraph",
                            "text": "Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma"
                        },
                        {
                            "section": "Paragraph",
                            "text": "If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer was originally published by the National Cancer Institute.”"
                        },
                        {
                            "section": "Paragraph",
                            "text": "February 13, 2025, by Carmen Phillips"
                        },
                        {
                            "section": "Paragraph",
                            "text": "January 2, 2025, by Linda Wang"
                        },
                        {
                            "section": "Paragraph",
                            "text": "December 11, 2024, by Nadia Jaber"
                        },
                        {
                            "section": "Paragraph",
                            "text": "National Cancer Institute\nat the National Institutes of Health"
                        }
                    ],
                    "related_links": [
                        "https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations#main-content",
                        "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States).",
                        "mailto:?subject=Information%20from%20the%20National%20Cancer%20Institute%20Web%20Site%20&body=I%20found%20this%20information%20on%20www.cancer.gov%20and%20I%27d%20like%20to%20share%20it%20with%20you:%20https://www.cancer.gov/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations%20%0D%0A%0D%0A%20NCI%27s%20Web%20site,%20www.cancer.gov,%20provides%20accurate,%20up-to-date,%20comprehensive%20cancer%20information%20from%20the%20U.S.%20government%27s%20principal%20agency%20for%20cancer%20research.%20If%20you%20have%20questions%20or%20need%20additional%20information,%20we%20invite%20you%20to%20contact%20NCI%27s%20LiveHelp%20instant%20messaging%20service%20at%20https://livehelp.cancer.gov,%20or%20call%20the%20NCI%27s%20Contact%20Center%201-800-4-CANCER%20(1-800-422-6237)%20(toll-free%20from%20the%20United%20States)."
                    ],
                    "related_pages": {}
                }
            }
        }
    }
}